Responses
Poster Presentations
Cytokines and inflammatory mediators
THU0038 Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells
Compose a Response to This Article
Other responses
No responses have been published for this article.